SEC Form 4 · accession 0001209191-19-011486
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott Biller
Officer — Chief Scientific Officer
Period of report
Feb 16, 2019
Accepted (ET)
Feb 20, 2019 · 4:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF1 | Feb 16, 2019 | M | 2,750 | — | A | 27,387 | D | |
| Common stock | Feb 19, 2019 | F | 876 | $58.03 | D | 26,511 | D | |
| Common stockF2 | holding | — | — | — | 53,059 | I | See footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted stock unitsF1,F3 | — | Feb 16, 2019 | M | 2,750 | D | — | — | Common stock | 2,750 | 5,500 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- F2Shares held by a spousal lifetime access trust, of which the reporting person's wife is the trustee.
- F3The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested.